e18690Background: CABOSUN, a randomized and open-label phase II trial, demonstrated significant improvement in progression-free survival (PFS) with cabozantinib versus sunitinib in the first-line t... Click to show full abstract
e18690Background: CABOSUN, a randomized and open-label phase II trial, demonstrated significant improvement in progression-free survival (PFS) with cabozantinib versus sunitinib in the first-line t...
               
Click one of the above tabs to view related content.